Is Neurogene Inc. (NGNE) a Buy, Sell, or Hold?
Neurogene Inc.
NASDAQ:NGNE
$39.45 USD
$0.37 (0.95%)
- Volume
- 181.59K
- Average Volume
- 210.89K
- Market Capitalization
- $623.4M
- P/E Ratio
- -7.84
- Dividend Yield
- 0.00%
- Price Target
- $70.00
- Year High
- $43.66
- Year Low
- $15.93
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $13.08
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Rachel L. McMinn |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | NGNE |
| CUSIP | 64135M105 |
| CIK | 0001404644 |
| Web | https://www.neurogene.com |
| Phone | (877) 237-5020 |
| Currency | USD |
| Employees | 131 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.04 |
| Payout Ratio | 0.00 |
| Current Ratio | 13.08 |
| Quick Ratio | 13.08 |
| Cash Ratio | 6.58 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -3.70 |
| Price / Cash Flow | -7.55 |
| Price / Book | 3.70 |
Price Target and Rating
| Average Stock Price Forecast | $70.00 |
| High Stock Price Forecast | $70.00 |
| Low Stock Price Forecast | $69.00 |
| Forecast Upside/Downside | -43.64% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-4.24 |
| Trailing P/E Ratio | -7.84 |
| PEG Ratio | 0.96 |
| P/E Growth | 0.96 |
| Net Income | $-90.35M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -37.88% |
| Return on Assets | -37.48% |
Financials Score
| AltmanZ Score | 12.09 |
| Piotroski Score | 1.00 |
| Working Capital | 227.88M |
| Total Assets | 263.14M |
| Ebit | -98.64M |
| Market Cap | 605.55M |
| Total Liabilities | 25.36M |
Poll Results
About Neurogene Inc. (NASDAQ:NGNE) Stock
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York. ...
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-06 16:01:00
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 96,450 shares of the Company's common stock to six new employees (the “Inducement Grants”) on July 6, 2026 (the “Grant Date”). The Inducemen.
Neurogene Inc. Announces Pricing of $125 Million Public Offering
2026-07-01 07:00:00
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the pricing of its previously announced public offering of 3,500,000 shares of its common stock at a public offering price per share of $30.00 and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 666,666 shares of its common stock at a public offerin.
Neurogene Inc. Announces Proposed Public Offering
2026-06-30 16:01:00
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, Neurogene expects to grant the underwriters a 30-day option to purchase additi.
2026-06-29 14:02:09
Neurogene Inc. (NGNE) Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome Transcript
2026-06-29 08:00:00
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
2026-06-29 07:00:00
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced updated, positive data from its Phase 1/2 clinical trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. Across 10 participants, 47 total developmental milestones were gained (average of 4.7 per participant), with both pediatric and adolescent/adult par.
2026-06-08 08:00:00
Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological
2026-06-08 07:30:00
NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the successful completion of dosing in the Embolden™ registrational trial of NGN-401, an investigational gene therapy designed to be a potential best-in-class, one-time treatment for Rett syndrome. While the initial enrollment target was 20 participants, the statistical analysis plan p.
Frequently Asked Questions
-
What is the current Neurogene Inc. (NGNE) stock price?
-
Neurogene Inc.(NASDAQ:NGNE) stock price is $39.45 in the last trading session. During the trading session, NGNE stock reached the peak price of $43.66 while $15.93 was the lowest point it dropped to. The percentage change in NGNE stock occurred in the recent session was 0.95% while the dollar amount for the price change in NGNE stock was $0.37.
-
NGNE's industry and sector of operation?
-
The NASDAQ listed NGNE is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of NGNE?
-
Julie Jordan | Chief Medical Officer
Rachel L. McMinn | Founder, Executive Chair & Chief Executive Officer
Arvind Sreedharan | Senior Vice President of Business Operations
Ricardo Jimenez | Senior Vice President of Technical Operations
Andrew E. Mulberg FAAP | Senior Vice President of Regulatory Affairs, Quality Assurance & Quality Control -
How many employees does NGNE have?
-
Number of NGNE employees currently stands at 131. NGNE operates from 535 W 24th Street, New York City, NY 10011, US.
-
Link for NGNE official website?
-
Official Website of NGNE is: https://www.neurogene.com
-
How do I contact NGNE?
-
NGNE could be contacted at phone #(877) 237-5020 and can also be accessed through its website. NGNE operates from 535 W 24th Street, New York City, NY 10011, US.
-
How many shares of NGNE are traded daily?
-
The average number of NGNE shares traded daily for last 3 months was 210.89K.
-
What is the market cap of NGNE currently?
-
The market value of NGNE currently stands at $623.4M with its latest stock price at $39.45